Comparing the Efficacy of Ticagrelor and Clopidogrel in Patients with Acute Ischemic Stroke
Keywords:
Stroke, Clopidogrel, TicagrelorAbstract
Introduction: This study compared the effects of using clopidogrel and ticagrelor for 90 days in reducing the risk of subsequent stroke or death and reducing related clinical symptoms, severe bleeding, and disability among patients with ischemic stroke.
Methods: The study was conducted as a randomized controlled clinical trial among patients with ischemic stroke referred to Golestan Hospital, Ahvaz. Two groups of patients were included and divided into each group in a 1:1 ratio using a simple random allocation method. The two groups received ticagrelor or clopidogrel plus aspirin within 24 hours after the onset of symptoms for 30 days. The trial's outcome was the combined risk of major ischemic events at 90 days. It was measured by the mRS (Modified Rankin Score) criterion and the incidence of recurrent stroke.
Results: In this study, 185 patients were studied in the ticagrelor + aspirin group and 187 in the clopidogrel + aspirin group. Comparing the two groups regarding the incidence of recurrent stroke at 90-day follow-up showed that the difference between the two groups was not significant, despite the higher percentage of recurrent stroke in the clopidogrel + aspirin group (9.1% vs. 7.0%) (P = 0.465).
Comparing the two groups regarding stroke outcome based on the mRS criterion at 90-day follow-up revealed that the mean mRS in the clopidogrel + aspirin group was significantly lower (1.87 ± 1.67 vs. 2.37 ± 1.79; P = 0.005).
Discussion and Conclusion: Based on the results, the two drug groups were not statistically significant regarding stroke outcomes. Since all cases of hemorrhagic transformation occurred in NIHSS ≥5, we should treat with caution in prescribing dual antiplatelet agents in these people.
Downloads
Metrics
References
Fiuji H, Namayandeh S, Erfani M. Epidemiologic study of the main risk factors for one-year ischemic stroke and surivial in patients admitted to the Neurology Department of Ghayim Hospital in Mashhad, Iran, 2015. Tolooebehdasht. 2020;19(2):33-42.
Schouten EA, Schiemanck SK, Brand N, Post MW. Long-term deficits in episodic memory after ischemic stroke: evaluation and prediction of verbal and visual memory performance based on lesion characteristics. Journal of stroke and cerebrovascular diseases. 2009;18(2):128-38.
Randolph SA. Ischemic stroke. Workplace health & safety. 2016;64(9):444.
Amarenco P, Lavallée PC, Labreuche J, Albers GW, Bornstein NM, Canhão P, et al. One-year risk of stroke after transient ischemic attack or minor stroke. New England Journal of Medicine. 2016;374(16):1533-42.
Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2019;50(12): e344-e418
Johnston S, Amarenco P, Albers G, Denison H, Easton J, Evans S, et al. SOCRATES Steering Committee and Investigators. Ticagrelor versus aspirin in acute stroke or transient ischemic attack. N Engl J Med. 2016;375(1):35-43.
Bowry AD, Brookhart MA, Choudhry NK. Meta-analysis of the efficacy and safety of clopidogrel plus aspirin as compared to antiplatelet monotherapy for the prevention of vascular events. The American journal of cardiology. 2008;101(7):960-6.
Storey RF, Husted S, Harrington RA, Heptinstall S, Wilcox RG, Peters G, et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. Journal of the American College of Cardiology. 2007;50(19):1852-6.
Wang Y, Minematsu K, Wong KSL, Amarenco P, Albers GW, Denison H, et al. Ticagrelor in acute stroke or transient ischemic attack in Asian patients: from the SOCRATES trial (acute stroke or transient ischemic attack treated with aspirin or ticagrelor and patient outcomes). Stroke. 2017;48(1):167-73.
Cesarini, D.; Muraca, I.; Berteotti, M.; Gori, A.M.; Sorrentino, A.; Bertelli, A.; Marcucci, R.; Valenti, R. Pathophysiological and Molecular Basis of the Side Effects of Ticagrelor: Lessons from a Case Report. Int. J. Mol. Sci. 2023, 24, 10844. https://doi.org/10.3390/ ijms241310844
Johnston SC, Amarenco P, Denison H, Evans SR, Himmelmann A, James S, et al. Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA. New England Journal of Medicine. 2020;383(3):207-17.
Johnston SC, Easton JD, Farrant M, Barsan W, Conwit RA, Elm JJ, et al. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. New England Journal of Medicine. 2018;379(3):215-25.
Wang D, Gui L, Dong Y, Li H, Li S, Zheng H, et al. Dual antiplatelet therapy may increase the risk of non-intracranial haemorrhage in patients with minor strokes: a subgroup analysis of the CHANCE trial. Stroke and Vascular Neurology. 2016;1.(2)
Liu L, Wong KSL, Leng X, Pu Y, Wang Y, Jing J, et al. Dual antiplatelet therapy in stroke and ICAS: subgroup analysis of CHANCE. Neurology. 2015;85(13):1154-62.
Brilakis ES, Patel VG, Banerjee S. Medical management after coronary stent implantation: a review. Jama. 2013;310(2):189-98.
Wallentin L, James S, Storey RF, Armstrong M, Barratt BJ, Horrow J, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. The Lancet. 2010;376(9749):1320-8.
Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, Held P, et al. Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial. The Lancet Neurology. 2017;16(4):301-10.
Cuisset T, Frere C, Quilici J, Barbou F, Morange P, Hovasse T, et al. High post‐treatment platelet reactivity identified low‐responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. Journal of Thrombosis and Haemostasis. 2006;4(3):542-9.
Fiolaki A, Katsanos AH, Kyritsis AP, Papadaki S, Kosmidou M, Moschonas IC, et al. High on treatment platelet reactivity to aspirin and clopidogrel in ischemic stroke: A systematic review and meta-analysis. Journal of the neurological sciences. 2017; 376:112-6.
Gupta K, Attri J, Singh A, Kaur H, Kaur G. Basic concepts for sample size calculation: critical step for any clinical trials! Saudi journal of anaesthesia. 2016;10(3):328.
Wang Y, Chen W, Lin Y, Meng X, Chen G, Wang Z, et al. Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack: open label, blinded endpoint, randomised controlled phase II trial. bmj. 2019;365.
Samuel OW, Fang P, Chen S, Geng Y, Li G. Activity recognition based on pattern recognition of myoelectric signals for rehabilitation. In: Khan SU, Zomaya AY, Abbas A, editors. Handbook of large-scale distributed computing in smart healthcare. Basel: Springer International Publishing AG; 2017.
Zihni E, McGarry BL, Kelleher JD. Moving Toward Explainable Decisions of Artificial Intelligence Models for the Prediction of Functional Outcomes of Ischemic Stroke Patients. In: Linwood SL, editor. Digital Health [Internet]. Brisbane (AU): Exon Publications; 2022 Apr 29.
Johnston SC, Amarenco P, Denison H, Evans SR, Himmelmann A, James S, et al. Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA. New England Journal of Medicine. 2020;383(3):207-17.
Johnston SC, Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, et al. Ticagrelor versus aspirin in acute stroke or transient ischemic attack. New England Journal of Medicine. 2016;375(1):35-43.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
